American Society of Hirudotherapy

Do that to me one more time! What kind of trial replications do we need?

Lüdtke R (2008) · Complementary Therapies in Medicine

Expert opinion / guidance: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.

Study Profile

Type
invited editorial on the methodological need for and design of replication trials in leech therapy and complementary medicine generally (Karl and Veronica Carstens Foundation, Germany)
Scope
Editorial discussion of replication-trial design - direct replication versus methodologically improved replication, sham control issues, meta-analytic considerations

Key Findings

  • Editorial by Karl and Veronica Carstens Foundation methodologist Rainer Lüdtke, co-author of the Michalsen 2003 landmark RCT
  • Argues for methodologically improved replication trials (especially adding sham control) over direct replication
  • Specifically discusses leech therapy in the context of broader complementary-medicine trial replication
  • Provides methodological framing for understanding why the field has progressively shifted from open-label to sham-controlled designs

Limitations

  • Editorial only - not primary evidence
  • No empirical data
  • Reflects 2008 methodological state-of-the-art - subsequent literature has advanced
  • Single-author opinion piece
  • No GRADE rating

Clinical Implications

Lüdtke 2008 is an important methodological reference for understanding the trajectory of the leech-therapy RCT literature. It documents the moment when the field recognized that further open-label replication was less valuable than sham-controlled and methodologically-improved designs. For ASH editorial-board purposes, this editorial provides historical context for the moderate GRADE rating applied to the knee OA evidence base: the field acknowledges that current evidence is moderate-quality precisely because the foundational Michalsen 2003 trial was open-label, and later design improvements (such as the Andereya 2008 'artificial leech' control) have not yet fully closed the gap.

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.